Randall Bateman, MD
Randall J. Bateman, M.D. is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.
Dr. Bateman’s laboratory investigates the causes, and future diagnosis and treatments of Alzheimer's disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer's disease. Dr. Bateman’s lab measures the pathophysiology of Alzheimer's disease in humans and measures amyloid-beta isoform kinetics in Alzheimer's disease. Dr. Bateman trains postdoctoral fellows, graduate students, and undergraduates in his lab.
Dr. Bateman led the development of a technique known as stable isotope-linked kinetics (SILK) that made it possible to determine that clearance of amyloid beta is impaired in patients with Alzheimer’s disease. Bateman and his colleagues are now studying whether alterations in amyloid beta clearance levels can be used to predict Alzheimer’s disease years before symptoms become apparent. Their goal is to prevent damage and loss of brain cells by intervening early in the disease process.
Dr. Bateman is the Director of the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) which is launching the first clinical trials in autosomal dominant Alzheimer’s disease (ADAD) aiming to prevent the onset of memory impairment and dementia. Dr. Bateman led efforts to form the first pharma consortium focused on ADAD, the DIAN Pharma Consortium (a collaboration of 10 pharmaceutical companies), and was granted the “largest-ever” Alzheimer’s Association research grant for the DIAN-TU. In 2010, he organized the Autosomal Dominant Alzheimer’s Disease Forum, a patient and family advocacy group for individuals affected by ADAD. Dr. Bateman also serves as the Associate Director and Clinical Core Leader of the DIAN, an international collaboration of leading research centers dedicated to studying ADAD.
Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University. He is also an investigator for the Charles F. and Joanne Knight Alzheimer’s Disease Research Center and for the Hope Center for Neurological Disorders. He is an inventor of several pending patents and an issued patent, and the scientific co-founding member of C2N Diagnostics, a biotechnology company located at the Center for Emerging Technology in St. Louis.
Dr. Bateman’s honors include the AAN Foundation Corporate Roundtable Clinical Research Fellowship, an American Neurological Association Plenary Session Speaker, a World Technology Award Nominee for Health and Medicine Associate, Scientific American 50 Award recognizing the top 50 scientific achievements of 2006, the Kopolow Award, the 2007 Alzheimer’s Research Forum Community Award, the Beeson Award, the St. Louis Academy of Science Innovator of the Year award, the Co-recipient of the Health Care Heroes in Innovation by the St. Louis Business Journal, the Glenn Award for Research, the 2011 Alzheimer’s Association Zenith Fellows Award, the 2011 Alzheimer’s Research Forum Open Innovation Award, the 2012 MetLife Promising Investigator Award.
His membership in honorary societies includes the American Neurological Association and the American Society for Clinical Investigation Council. Dr. Bateman’s professional memberships include the American Academy of Neurology and the Society for Neuroscience. He serves as an editor and reviewer for many prominent scientific journals and is a sought-after lecturer nationally and internationally.
Dr. Bateman attended Washington University where he received a B.S. degree in Biology (1995) and a B.S. degree in Electrical Engineering (1995). He attended Case Western Reserve University School of Medicine where he received his M.D. (2000) with special emphasis on the neurosciences. He completed a medical internship (2001) at Barnes-Jewish Hospital followed by Neurology residency (2004) at Washington University in St. Louis. He then completed post-doctoral research training with David M. Holtzman, M.D. as mentor and clinical research fellowship training at the Washington University ADRC with John Morris, M.D. as mentor. Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University.
Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim, J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, Holtzman DM, Bateman RJ. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 2012; 7(6):e38013. Epub 2012 Jun 4. PMID:22675504; PMCID: PMC3366983
Castellano JM, Kim J, Stewart FR, Jiang H, Demattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE Isoforms Differentially Regulate Brain Amyloid- Peptide Clearance. Sci Transl Med. 2011 Jun 29;3(89):89ra57. PMC Journal - In Process. PMID#21715678
Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju Y, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ. Effects of Age and Amyloid Deposition on Aβ Dynamics in the Human Central Nervous System. Archives of Neurology. Published online September 12, 2011. doi:10.1001/archneurol.2011.235. NIHMS326112
Zanier ER, Refai D, Zipfel GJ, Zoerle T, Longhi L, Esparza TJ, Spinner ML, Bateman RJ, Brody DL, Stocchetti N. Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2011;82(2):157-9. PMID: 20571038. PMID:20571038
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer’s Res Ther. 2011 Jan 6;2(6):35. PMCID: PMC3109410
Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, Suzuki T. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: Evidence for γ-secretase dysfunction. Annals of Neurology 2010; doi: 10.1002/ana.22343. PMID:21681798
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased Clearance of CNS Amyloid-β in Alzheimer ’s disease. Science December 2010: 330 (6012): 1774.
Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010;30:6743-50.
Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-Aβ Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science 2009;326:1005-7.
Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Analytical Biochemistry 2009;395:116-8.
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology 2009;66:48-54.
Elbert DL, Mawuenyega KG, Scott EA, Wildsmith KR, Bateman RJ. Stable Isotope Labeling Tandem Mass Spectrometry (SILT): Integration with Peptide Identification and Extension to Data-Dependent Scans. J Proteome Res 2008;7:4546-56.
Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics 2008;5:381-90.
Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable Isotope Labeling Tandem Mass Spectrometry (SILT) to Quantify Protein Production and Clearance Rates. Journal of the American Society for Mass Spectrometry 2007;18:997-1006.
Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9.
Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006.
Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-61.
© 2006-2012 Washington University School of Medicine